Regional Sales Director-Breast Cancer (West Region)

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. ELZONRIS® (tagraxofusp) is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To date, Elzonris is the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

In Europe, Menarini Stemline also commercializes Nexpovio®, a first-in-class oral exportin 1 (XPO1) inhibitor for multiple myeloma in the UK, Switzerland, European Economic Area, CIS countries, Latin America and Turkey. Nexpovio is approved for use in combination with dexamethasone for treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy; and in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma who have received at least one prior therapy. Nexpovio’s marketing authorization is valid in the EU Member States as well as Iceland, Liechtenstein, Norway, and Northern Ireland, and it has been commercially available in Germany and Austria since the fourth quarter of 2022.

In January 2023, Stemline Therapeutics, received U.S. FDA approval for ORSERDU™ (elacestrant), the first and only treatment specifically indicated for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. ESR1 mutations cause tumors to become resistant to endocrine therapy, and up to 40% of patients with ER+, HER2- mBC have tumors which harbor this mutation. ORSERDU is the first endocrine innovation in more than 20 years, and specifically addresses a major unmet need. Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. A Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA).

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumor Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB is offering in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Regional Sales Director- Solid Tumors (West Region)

Reports to Vice President, Head of Sales

Menarini Stemline is hiring a Regional Sales Director for our Solid Tumor portfolio. The Regional Sales Director is responsible for hiring, managing, training and developing the commercial customer facing sales representative team within their assigned geography. Additional responsibilities to include, but are not limited to assisting in the development of the regional account level sales strategy, expense management and analysis, engaging in KOL development, key customer engagement, and providing internal feedback on marketing strategies.

Responsibilities

Attainment of geographic business plan and revenue/product goals.

Develop direct reports to enhance performance, productivity, and employee satisfaction.

Formulate a local Budget and maintain budget within limits of +/- 3% of target.

Business plan implementation as measured by the following:

Key Account/KOL Development

Sales Team Performance and Development

New Account/Customer Acquisition

Marketing Strategy Implementation

Effective use of training, coaching, counseling, facilitating and delegating to establish the direction and environment for the professional development of staff.

Provide clear performance expectations, constructive feedback and take appropriate action in managing staff including but not limited to:

Field Day Coaching Evaluations

MBOs

Performance Evaluations

Performance Improvement Plan Management

Ride in Field/Observe/Coach/Train team members meeting minimum field day coaching requirements as established.

Complete Field Coaching Forms to document field coaching/ride-along with sales team.

Plan, develop, direct, evaluate and communicate results of area sales and marketing strategies.

Maintain product knowledge of responsible product categories sufficient to be able to coach and train team members.

Responsible for development and implementation of a Regional Strategic Business Plan

Developing, maintaining and improving relationships with key existing and potential customers

Manage staffing levels to anticipate needs created by business expansion, market conditions, and staffing changes.

Utilize strategic account targeting framework to assess staffing needs and support business objectives.

Interview and evaluate candidates using Targeted Selection process. Select the best qualified candidate in a timely manner.

Responsible for establishing, maintaining and enhancing effective teamwork relationships with staff and other internal customers.

Coordinate teamwork efforts with staff, colleagues and all corporate departments.

Effectively implement administrative procedures, company policies, and maintain company assets.

Maintain all Company assets according the company guidelines (e.g., Company Computer), and timely and accurate completion of Company reports, plans and procedures, to include but not limited to:

Business Plans

Expense Reports

Company asset tracking

Demonstrate professional development and growth.

Ability to work flexible hours and weekends to meet business/customer needs.

Participates in any and all reasonable work activities as assigned by management.

Skills/Knowledge

Strong business acumen with the ability to define and effectively communicate the appropriate sales model to deliver results and anticipate critical issues.

Solid sales and operational experience with high emphasis on analytics and Field Sales management discipline that was developed through leadership experience across the hematology and oncology disciplines.

Demonstrated behavior indicating a relentless attitude for winning.

Demonstrated ability to persevere.

Demonstrated principled leadership, including change management, and unyielding business and personal ethics; Ensure compliance with governmental regulations and maintaining honesty, integrity, and excellent work ethic.

Develop and implement business plans as the result of analyses and assessments.

Oversees the formulation of sales strategies and tactical execution.

Ability to lead a team, influence others, and handle increasing levels of responsibilities.

Possess strong analytical skills and is able to identify and provide solutions to complex issues.

Knowledge of sales and marketing principles.

Demonstrated ability to prioritize and execute tasks in a dynamic environment.

Executive-level verbal and written communication skills.

Highly advanced organizational and interpersonal skills are essential.

Understanding of industry trends and competitive strategy outlook in order to identify opportunities.

Set of diverse experiences affording the individual a broad business perspective as well as the ability to anticipate critical issues for the organization.

Intermediate to advanced skills with Microsoft Office (Excel, Word, PowerPoint, Outlook), and CRM Platforms.

Ability to work effectively with all employees and external business contacts while conveying a positive, service oriented attitude.

Ability to maintain complete confidentiality and discretion in business relationships and exercise sound business judgment.

Build Compliance into all aspects of their work by maintaining compliance to all Federal and State requirements.

Ensure compliance to all FDA and Worldwide Quality & Compliance regulations (As applicable to the job function).

Qualifications

Bachelor's degree in Business, Marketing, or Science related field required (Master's degree preferred).

Minimum of seven (7) years of successful sales experience in the biotech hematology and oncology sector, with operational experience in the breast cancer therapeutic area preferred

Minimum of three (3) years frontline sales management experience required.

Experience with other market-leading pharmaceutical or biotech organizations

Proven sales track record

Travel requirement of approximately 75%.

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.

Menarini Stemline is an equal-opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

Compensation package: Base Salary of $225,000-$270,000 plus Incentive Compensation

Permanent Full-Time